CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company, announced its financial results for the fourth quarter and full year ended December 31, 2025. The company reported a fourth quarter revenue of $3.9 million, representing a 13% increase compared to the same period in 2024. For the full year, revenue reached $13.6 million, marking a 15% increase from the previous year. This growth was primarily driven by an increase in the number of CapsoCam Plus capsules sold, which have been utilized by over 161,000 patients as of December 31, 2025.

In addition to revenue growth, CapsoVision highlighted a 16% increase in new accounts during the fourth quarter compared to the same quarter in 2024, and a 21% increase for the full year. The company also submitted a 510(k) application to the FDA for its AI-assisted module for CapsoCam Plus, indicating its commitment to advancing its product offerings.

Despite the positive revenue growth, the company reported a net loss of $25.3 million for the year, which reflects an increase in operating expenses primarily due to the development of new technologies and clinical trial activities. Operating expenses for the year totaled $32.7 million, up from $26.3 million in 2024. The company ended the year with cash and cash equivalents of $10.1 million, bolstered by a $14 million private placement completed in March 2026.

Management expressed optimism about the company's strategic progress and operational execution, emphasizing their focus on disciplined execution and continued investment in product innovation. The company plans to host a conference call to discuss these results further, indicating a proactive approach to investor relations and transparency.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.